Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 9/20 | 0.37 |
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | GGT1 | P19440 | 2/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941639 | 1.00 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCPB2 | |
| Glycine SCHEMBL29049703 | 0.89 | PTGS1 (0.50) | PTGS1SLC7A11ENPEPANPEPCPB2 | |
| Glycine SCHEMBL29049701 | 0.89 | PTGS1 (0.50) | PTGS1SLC7A11ENPEPANPEPCPB2 | |
| SCHEMBL31114352 | 0.89 | PTGS1 (0.44) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL30159759 | 0.87 | — | — | |
| SCHEMBL30159653 | 0.84 | PTGS1 (0.44) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL456395 | 0.83 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCPB2 | |
| SCHEMBL28547750 | 0.83 | PTGS1 (0.55) | PTGS1SLC7A11ENPEPANPEPCPB2 | |
| SCHEMBL31130601 | 0.81 | — | — | |
| SCHEMBL359013 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116519812-A | Application of biomarker in preparation of gestational diabetes diagnostic reagent | 杭州凯莱谱精准医疗检测技术有限公司 | 2023-08-01 | — | — | CN | claimed |
| US-20230272007-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS INC (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116519812-A | Application of biomarker in preparation of gestational diabetes diagnostic reagent | 杭州凯莱谱精准医疗检测技术有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20220119452-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210032292-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS INC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20180186835-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-9708371-B2 | Treatments for gastrointestinal disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2776055-B1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20150094272-A1 | Treatments for Gastrointestinal Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| EP-2776055-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013025969-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20100305311-A1 | NANOPARTICLE FOR SEPARATING PEPTIDE, METHOD FOR PREPARING THE SAME, AND METHOD FOR SEPARATING PEPTIDE USING THE SAME, | KOREA UNIVERSITY INDUSTRIAL & ACADEMIC COLLABORATION FOUNDATION | 2010-12-02 | — | — | US | disclosed |
| WO-2009069959-A2 | A NANOPARTICLE FOR SEPARATING PEPTIDE, METHOD FOR PREPARING THE SAME, AND METHOD FOR SEPARATING PEPTIDE USING THE SAME | KOREA UNIVERSITY INDUSTRIAL & ACADEMIC COLLABORATION FOUNDATION (KR) | 2009-06-04 | — | — | WO | disclosed |
| US-6028066-A | FOR DELIVERING HIGHER CONCENTRATIONS OF BIOACTIVE AGENTS TO IMPROVE EFFICACY OF THE BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1998050041-A1 | NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094272-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | PTGS1 155/4885SLC7A11 1999/4885ENPEP 371/4885 |
| US-20230272007-A1 | TREATMENTS FOR GASTROINTESTINAL DISORDERS | GRPR, GIPR, GCGR | PTGS1 156/4885SLC7A11 1998/4885ENPEP 375/4885 |
| US-20180186835-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | PTGS1 156/4885SLC7A11 1998/4885ENPEP 375/4885 |
| US-20220119452-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | PTGS1 156/4885SLC7A11 1998/4885ENPEP 375/4885 |
| US-20210032292-A1 | Treatments for Gastrointestinal Disorders | GRPR, GIPR, GCGR | PTGS1 156/4885SLC7A11 1998/4885ENPEP 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.